RHR: The Microbiome Approach to Better Probiotics, with Colleen Cutcliffe
In this episode, we discuss: The current probiotic marketplace—novel strains and formulations are starting to be discovered after not much new development since the 1970s The difference between aerobic and anaerobic strains and the emerging biotherapeutic agent Akkermansia How the gut microbiome influences everything about your health, and what Pendulum has discovered about these connections The gut–brain neurotransmitter relationship and the potential of novel strains in the treatment and prevention of Parkinson’s disease, Alzheimer’s disease, and autism Results of clinical trials with Akkermansia showing significantly lowered A1C and stabilized blood glucose levels The challenges to taking the microbiome approach, including the difficulty in manufacturing anaerobic strains and connecting microbiome science with actual health solutions Recommendations for taking the Pendulum line of therapeutics Show notes: [embedded content] Hey, everybody, Chris Kresser here. Welcome to...